Voya Investment Management LLC Blueprint Medicines Corp Transaction History

Voya Investment Management LLC

$86.1 Billion
Q1 2024

A detailed history of Voya Investment Management LLC transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Voya Investment Management LLC holds 103,074 shares of BPMC stock, worth $11.1 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

103,074

Previous 102,082 0.97%

Holding current value

$11.1 Million

Previous $9.42 Million 3.83%

% of portfolio

0.01%

Previous 0.01%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$73.17 - $99.79 $72,584 - $98,991	992 Added 0.97%	103,074 $9.78 Million
Q4 2023 Feb 14, 2024	SELL	$43.96 - $92.84 $2.34 Million - $4.94 Million	-53,221 Reduced 34.27%	102,082 $9.42 Million
Q3 2023 Nov 14, 2023	SELL	$46.9 - $66.0 $15,383 - $21,648	-328 Reduced 0.21%	155,303 $7.8 Million
Q2 2023 Aug 14, 2023	BUY	$42.2 - $66.37 $2.03 Million - $3.2 Million	48,179 Added 44.84%	155,631 $9.84 Million
Q1 2023 May 15, 2023	SELL	$37.97 - $50.0 $5,125 - $6,750	-135 Reduced 0.13%	107,452 $4.83 Million

Q4 2022 Feb 14, 2023	SELL	$41.06 - $66.48 $16,670 - $26,990	-406 Reduced 0.38%	107,587 $4.71 Million
Q3 2022 Mar 03, 2023	BUY	$49.93 - $77.7 $20,271 - $31,546	406 Added 0.38%	107,993 $7.12 Million
Q3 2022 Nov 14, 2022	BUY	$49.93 - $77.7 $1.34 Million - $2.09 Million	26,838 Added 33.07%	107,993 $7.12 Million
Q2 2022 Aug 15, 2022	SELL	$45.23 - $70.15 $1.6 Million - $2.48 Million	-35,289 Reduced 30.31%	81,155 $4.1 Million
Q1 2022 May 16, 2022	BUY	$54.1 - $110.08 $2.4 Million - $4.89 Million	44,382 Added 61.59%	116,444 $7.44 Million
Q4 2021 Feb 14, 2022	SELL	$94.25 - $115.99 $7.79 Million - $9.59 Million	-82,687 Reduced 53.43%	72,062 $7.72 Million
Q3 2021 Nov 15, 2021	BUY	$80.98 - $109.47 $2.58 Million - $3.49 Million	31,911 Added 25.98%	154,749 $15.9 Million
Q2 2021 Aug 16, 2021	SELL	$82.78 - $101.0 $2.07 Million - $2.53 Million	-25,022 Reduced 16.92%	122,838 $10.8 Million
Q1 2021 May 17, 2021	SELL	$90.71 - $108.28 $1.93 Million - $2.3 Million	-21,257 Reduced 12.57%	147,860 $14.4 Million
Q4 2020 Feb 16, 2021	SELL	$92.08 - $124.48 $4.65 Million - $6.28 Million	-50,456 Reduced 22.98%	169,117 $19 Million
Q3 2020 Nov 16, 2020	BUY	$66.45 - $92.7 $1.48 Million - $2.06 Million	22,223 Added 11.26%	219,573 $20.4 Million
Q2 2020 Aug 14, 2020	SELL	$57.09 - $79.27 $2.54 Million - $3.53 Million	-44,505 Reduced 18.4%	197,350 $15.4 Million
Q1 2020 May 15, 2020	SELL	$48.11 - $82.22 $473,931 - $809,949	-9,851 Reduced 3.91%	241,855 $14.1 Million
Q4 2019 Feb 14, 2020	SELL	$66.73 - $82.59 $6.39 Million - $7.91 Million	-95,794 Reduced 27.57%	251,706 $20.2 Million
Q3 2019 Nov 14, 2019	BUY	$72.9 - $101.41 $7.21 Million - $10 Million	98,836 Added 39.75%	347,500 $25.5 Million
Q2 2019 Aug 14, 2019	SELL	$73.54 - $97.8 $5.98 Million - $7.95 Million	-81,321 Reduced 24.64%	248,664 $23.5 Million
Q1 2019 May 15, 2019	SELL	$48.7 - $86.6 $2.49 Million - $4.42 Million	-51,047 Reduced 13.4%	329,985 $26.4 Million
Q4 2018 Feb 14, 2019	SELL	$45.57 - $74.26 $3.82 Million - $6.23 Million	-83,896 Reduced 18.04%	381,032 $20.5 Million
Q3 2018 Nov 14, 2018	BUY	$58.91 - $78.32 $1.65 Million - $2.2 Million	28,034 Added 6.42%	464,928 $36.3 Million
Q2 2018 Aug 14, 2018	BUY	$60.96 - $101.18 $7.28 Million - $12.1 Million	119,406 Added 37.61%	436,894 $27.7 Million
Q1 2018 May 15, 2018	BUY	$73.28 - $102.95 $21.9 Million - $30.7 Million	298,594 Added 1580.36%	317,488 $29.1 Million
Q4 2017 Feb 14, 2018	BUY	$62.91 - $88.32 $44,037 - $61,823	700 Added 3.85%	18,894 $1.43 Million
Q3 2017 Nov 14, 2017	BUY	$42.37 - $69.67 $770,879 - $1.27 Million	18,194	18,194 $1.27 Million

Others Institutions Holding BPMC

# of Institutions

313

Shares Held

60.6M

Call Options Held

634K

Put Options Held

691K

View Full List

About Blueprint Medicines Corp

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $6.44B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

More about BPMC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Voya Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Voya Investment Management LLC with notifications on news.

Account

Voya Investment Management LLC Blueprint Medicines Corp Transaction History